Pharmaceutical News

RSS

Taiho Pharmaceutical seeks Japanese approval for TAS-102 to treat colorectal cancer

Taiho Pharmaceutical Co., Ltd. announced on February 27 that it submitted an application on February 26 for approval of the manufacture and marketing of the novel oral nucleoside antitumor agent TAS-102 (combination of trifluorothymidine (FTD) and tipiracil hydrochloride (TPI)) to the Japanese Ministry of Health, Labor and Welfare.

27 Feb 2013

XBiotech to enter biosimilar business

XBiotech, a privately held biotechnology company, announced today that it is entering the biosimilar business. The Company is launching its biosimilar business with development of two of the world's leading therapeutic antibodies, one an oncology and the other an anti-inflammatory product.

26 Feb 2013

Baxter files FEIBA NF BLA with FDA for prophylactic treatment of hemophilia A or B

Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) supplement to the U.S. Food and Drug Administration (FDA) for the approval of prophylaxis treatment of FEIBA NF [Anti-Inhibitor Coagulant Complex], Nanofiltered and Vapor Heated, in patients with hemophilia A or B and inhibitors.

From Baxter International Inc. 26 Feb 2013

Genetic variation in CD33 influences how AML patients' leukemic cell responds to GO

Researchers from the College of Pharmacy and Medical School working within the Masonic Cancer Center, University of Minnesota, have partnered to identify genetic variations that may help signal which acute myeloid leukemia (AML) patients will benefit or not benefit from one of the newest antileukemic agents.

26 Feb 2013

IFR, PBL to further develop Dynamic Gastric Model

The Dynamic Gastric Model, developed from years of research at the Institute of Food Research, has taken significant steps towards improving its commercial use by food and drug companies worldwide.

26 Feb 2013

Shionogi receives FDA approval for Osphena to treat women with severe dyspareunia

The U.S. Food and Drug Administration today approved Osphena (ospemifene) to treat women experiencing moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy due to menopause.

26 Feb 2013

Pharmaceutical research centre led by the University of Limerick to receive investment from Science Foundation Ireland

A research centre led by the University of Limerick dedicated to supporting the pharmaceutical industry in Ireland will benefit from today’s announcement of €300 million investment by Science Foundation Ireland. The Irish pharmaceutical industry supports over 60,000 Irish jobs and exports over €50 billion annually.

26 Feb 2013

Complementary medicine risks: an interview with Dr Andrew Boyden, NPS MedicineWise

Complementary medicines include products containing herbs, vitamins, minerals, nutritional supplements, homoeopathic medicines, certain aromatherapy products and traditional Chinese medicines. For this reason they are also called herbal, natural or alternative medicines.

26 Feb 2013

Anemia medication recall could affect thousands of kidney-disease patients

The recall comes as a sharp blow to Affymax, a small biotechnology firm based in Palo Alto, Calif., that developed Omontys and has no other late-stage drugs in its pipeline.

26 Feb 2013

New UM technology could provide five-minute diagnostic test and vaccine for Staph infections

New technology from the University of Maryland (UM) could potentially provide a five-minute diagnostic test and a vaccine for tough-to-treat Staphylococcus aureus infections, including the antibiotic-resistant MRSA, often called a "super bug," says inventor Mark Shirtliff, PhD, an associate professor at the UM School of Dentistry in Baltimore.

26 Feb 2013

Xellia to develop new antibiotics effective against multi-drug resistant Gram-negative bacteria

Xellia Pharmaceuticals, a fully integrated specialty pharmaceutical company focusing on the global anti-infective market, announced today that it is developing new antibiotics effective against multi-drug resistant (MDR), Gram-negative bacteria.

26 Feb 2013

HDAC-mediated mechanisms play critical role in regulating lung repair and regeneration

Lung diseases such as asthma and chronic obstructive pulmonary disease (COPD) are on the rise, according to the American Lung Association and the National Institutes of Health.

26 Feb 2013

FDA approves Actavis’ generic Suboxone ANDA to treat opioid dependence

Actavis, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Buprenorphine HCl and Naloxone HCl Dihydrate SL Tablets, 2 mg/0.5 mg and 8 mg/2 mg, the generic equivalent to Reckitt Benckiser Healthcare's Suboxone.

26 Feb 2013

Bayer receives FDA approval for Stivarga to treat advanced gastrointestinal stromal tumors

The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafenib) to treat patients with advanced gastrointestinal stromal tumors (GIST) that cannot be surgically removed and no longer respond to other FDA-approved treatments for this disease.

26 Feb 2013

GLP-1 may increase risk of hospitalization for people with acute pancreatitis

People who take the newest class of diabetes drugs to control blood sugar are twice as likely as those on other forms of sugar-control medication to be hospitalized with pancreatitis, Johns Hopkins researchers report.

25 Feb 2013

Novel anti-cancer drug conjugates to be evaluated by Ablynx and Spirogen

Ablynx [Euronext Brussels: ABLX] and Spirogen Ltd. announce a research collaboration to evaluate the potential of a novel anti-cancer drug conjugate combining Spirogen's proprietary cytotoxic drugs, pyrrolobenzodiazepines (PBD), and associated linker technology, with Nanobodies® generated using Ablynx’s proprietary technology platform.

25 Feb 2013

Comprehensive portfolio of antiretroviral products from Mylan

Mylan Inc., one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary in South Africa, Mylan (Proprietary) Limited, has launched a comprehensive portfolio of antiretroviral (ARV) products.

25 Feb 2013

FDA alerts patients and health care providers of voluntary recall of Omontys by Affymax

The U.S. Food and Drug Administration is alerting health care providers and patients of a voluntary nationwide recall of all lots of Omontys Injection by Affymax, Inc., of Palo Alto, Calif., and Takeda Pharmaceuticals Company Limited, of Deerfield, Ill.

25 Feb 2013

FDA approves Amneal’s generic Suboxone to treat opioid drug dependence

Amneal Pharmaceuticals, LLC, the 7th largest generic drug manufacturer in the U.S. market, has received U.S. FDA approval for one of the first generic versions of Suboxone sublingual tablets for maintenance treatment of opioid drug dependence.

25 Feb 2013

Systemic delivery of antisense oligonucleotides neutralizes mutant RNA toxicity in mice with DM1

By targeting the specific mutation that causes the hereditary neuromuscular disease myotonic dystrophy, it is possible to neutralize the mutant RNA toxicity and minimize or even eliminate the disabling symptoms of the disease.

25 Feb 2013

Pharmaceutical News

Taiho Pharmaceutical seeks Japanese approval for TAS-102 to treat colorectal cancer

XBiotech to enter biosimilar business

Baxter files FEIBA NF BLA with FDA for prophylactic treatment of hemophilia A or B

Genetic variation in CD33 influences how AML patients' leukemic cell responds to GO

IFR, PBL to further develop Dynamic Gastric Model

Shionogi receives FDA approval for Osphena to treat women with severe dyspareunia

Pharmaceutical research centre led by the University of Limerick to receive investment from Science Foundation Ireland

Complementary medicine risks: an interview with Dr Andrew Boyden, NPS MedicineWise

Anemia medication recall could affect thousands of kidney-disease patients

New UM technology could provide five-minute diagnostic test and vaccine for Staph infections

Xellia to develop new antibiotics effective against multi-drug resistant Gram-negative bacteria

HDAC-mediated mechanisms play critical role in regulating lung repair and regeneration

FDA approves Actavis’ generic Suboxone ANDA to treat opioid dependence

Bayer receives FDA approval for Stivarga to treat advanced gastrointestinal stromal tumors

GLP-1 may increase risk of hospitalization for people with acute pancreatitis

Novel anti-cancer drug conjugates to be evaluated by Ablynx and Spirogen

Comprehensive portfolio of antiretroviral products from Mylan

FDA alerts patients and health care providers of voluntary recall of Omontys by Affymax

FDA approves Amneal’s generic Suboxone to treat opioid drug dependence

Systemic delivery of antisense oligonucleotides neutralizes mutant RNA toxicity in mice with DM1

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News